CTLA4 and liver cancer: Preclinical and clinical studies also show that the immune checkpoint therapy provides a survival benefit for some significant number of patients with liver cancer, and a combination of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies is an effective treatment strategy forhepatocellular carcinoma (HCC) [9, 10].